CD68 and neoplasm: Alternatively, we showed that anti-mouse CD68 IHC of aEGFRvIII-SGRP CAR-treated brains on day 13 post-tumor implantation (compared to day 21 for all other conditions; Supplementary Fig. 6a) had a more pronounced density of GAMs on sites of tumor scarring (Supplementary Fig. 6e–g).